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 Epidemiology 
 New epidemiological data come from a study per-
formed in Argentina  [2] , showing that g-NENs and
d-NENs represent 6.9 and 2.0% of all digestive NENs, 
respectively. These data are similar to the SEER data, 
where g-NENs were found to represent 8.7% of all en-
teric NENs  [3] , and quite similar to a recent prospective 
Austrian study by Niederle et al.  [4] , where g-NENs rep-
resented 5.6% of all digestive NENs. The proportions of 
g-NENs with respect to the overall NEN rates do vary, 
however; g-NENs represented 23% of all NENs in the 
Austrian study compared to 6% in the SEER data, 5% in 
a Canadian study (Ontario) and 7.4% in a Taiwanese 
study  [4–7] . These differences underline the need for 
multicenter prospective studies with long-term analysis 
to better describe the European epidemiology of these 
tumors.
 Introduction 
 Gastric neuroendocrine neoplasms (g-NENs) repre-
sent the most frequent digestive NENs and are increas-
ingly recognized due to expanding indications of upper 
gastrointestinal endoscopy. Often silent and benign, g-
NENs may however be aggressive when sporadic and may 
sometimes mimic the course of gastric adenocarcinoma. 
Duodenal neuroendocrine neoplasms (d-NENs) may be 
sporadic or associated with multiple endocrine neoplasia 
type 1 (MEN-1) and present with a functional syndrome 
(i.e. gastrinoma with Zollinger-Ellison syndrome). 
 Since the last ENETS guidelines  [1] , new data have be-
come available, especially focusing on g-NENs, while few 
changes have been reported concerning d-NENs over the 
last three years.
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 Clinical and Histological Features 
 Well-differentiated g-NENs may be divided into three 
types ( table 1 ): type 1 and 2 are ECLomas, due to chron-
ic hypergastrinemia, associated with chronic atrophic 
gastritis (CAG) and Zollinger-Ellison syndrome, respec-
tively. Type 3 g-NENs are rare and sporadic and are not 
a consequence of an underlying gastric mucosal abnor-
mality; they are mostly single large lesions with a high 
metastatic potential and with a high grade (often G3 
NEC)  [8, 9] . Some issues remain open with respect to the 
above definitions, as well-differentiated g-NENs with a 
range of grades (G1–G3) not associated with CAG have 
been described  [10–12] , and thus a further distinction 
among type 3 g-NENs may be appropriate. Mixed gas-
tric neoplasms as endocrine/exocrine have also been de-
scribed; 68 cases have been reported in the literature so 
far, but no data about the patients’ survival rate are avail-
able  [13] .
 Prognosis and Survival 
 The overall outcome in type 1 g-NENs is universally 
excellent; when managed by endoscopic surveillance 
and lesion resection for larger lesions, recurrence-free 
survival of approximately 24 months can be achieved 
with a 100% survival rate. Data on metastatic rates for 
types 2 and 3 g-NENs have not significantly changed 
since the last ENETS guidelines  [1, 14] . Similarly, no 
new data regarding d-NENs survival rates have been re-
ported.
 Diagnosis and Tumor Staging 
 Upper gastrointestinal endoscopy with careful ap-
praisal of the tumor(s) and background gastric mucosa is 
still the gold standard in diagnosing g- and d-NENs. En-
doscopic ultrasonography also plays a pivotal role in lo-
coregional evaluation, but the cut-off in terms of size 
when defining the indication for this examination in type 
1 NENs needs to be investigated. Conventional imaging 
techniques such as CT scan and MRI are of very limited 
value for small type 1 and 2 tumors of the stomach and 
duodenum in terms of cost/benefit ratio, while they are 
needed for disease staging in advanced neoplasms and in 
type 3 NENs. Data concerning the application of soma-
tostatin receptor imaging (either using somatostatin re-
ceptor scintigraphy or  68 Ga-PET-DOTANOC) in these 
patients are scanty. These examinations are rarely useful 
for type 1 g-NENs that are invariably small and indolent, 
but they can be useful in type 2 and 3 g-NENs as part of 
the overall staging and perhaps choosing therapy  [15–
17] . Larger cohort studies with long-term follow-up are 
needed to evaluate the clinical usefulness of these tests 
both in g- and in d-NENs.
 Treatment 
 In patients with type 1 g-NENs ( fig. 1 ), conservative 
management strategies are to be preferred over surgery. 
Previously, the ENETS guidelines recommended surveil-
lance after 1–2 years and resection for lesions  ≥ 1 cm or 
those threatening the deep muscularis propria to avoid 
 Table 1.  Classification of g-NENs
Type 1 Type 2 Type 3
Proportion among g-NENs, % 70 – 80 5 – 6 14 – 25
Tumor characteristics Often small (<1 – 2 cm), multiple in 
65% of cases, polypoid in 78% of cases
Often small (<1 – 2 cm) 
and multiple, polypoid
Unique, often large (>2 cm) 
polypoid and ulcerated
Associated conditions Atrophic body gastritis Gastrinoma/MEN-1 None
Pathology G1–G2 NET G1–G2 NET G3 NEC
Serum gastrin levels ↑ ↑ Normal
Gastric pH ↑↑ ↓↓ Normal
Metastases, % 2 – 5 10 – 30 50 – 100
Tumor-related deaths, % 0 <10 25 – 30
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metastatic spread. Some investigators have advocated re-
secting all visible lesions using biopsy forceps for small 
lesions and endoscopic mucosal resection (EMR) for le-
sions >5 mm  [18, 19] ; however, there are no randomized 
data comparing an aggressive endoscopic approach (re-
secting all visible tumors) to more selective endoscopic 
therapy (resecting only larger lesions). The overall meta-
static risk is low in type 1 g-NENs and has been directly 
correlated with tumor size (10 mm appearing to be the 
cut-off)  [20] . Therefore, the minimal approach should be 
to resect tumors  ≥ 10 mm. Resection should be performed 
by experienced endoscopists in gastric tumors using ei-
ther EMR or endoscopic submucosal dissection (ESD); 
the latter has the benefit of an en bloc resection for com-
plete histological appraisal and has been shown effective 
in a total of 96 patients  [21–24] . Nonetheless, EMR and 
ESD do carry risks of bleeding and perforation. A ran-
domized trial comparing a less aggressive therapy to more 
aggressive endoscopic therapies is needed. It is also im-
portant to carefully analyze the non-involved adjacent 
gastric mucosa for dysplasia in a background of CAG, and 
mapping biopsies are recommended. For patients with 
type 1 tumors that are predicted T2 or with positive mar-
gins, local excision or partial gastrectomy should be dis-
cussed; surgical antrectomy to suppress hypergastrin-
emia and limit ECL growth is still debated  [1] but rarely 
practiced as completeness of antrectomy remains specu-
lative.
 Somatostatin analogues (SSAs) have been used in lim-
ited series in patients with type 1 g-NENs; they do lead to 
regression of tumors but this has not been compared to 
surveillance strategies and as such cannot be recom-
mended in early disease. SSAs might be useful to treat 
patients with multiple small lesions that are hard to erad-
icate endoscopically  [25] , but RCTs comparing their ef-
ficacy to endoscopic management are needed to confirm 
this hypothesis. Their use can be an option for patients 
with metastatic disease, proven SSTR2 expression and a 
low Ki-67 index. The gastrin receptor antagonist netaze-
pide has been shown to have anti-proliferative properties 
in g-NENs in non-controlled studies  [26, 27] . Again, its 
use cannot be universally recommended and needs to be 
tested in RCTs. 
 For type 2 g-NENs, treatment is usually dictated by the 
possible presence of duodenal or pancreatic NENs as part 
of MEN-1, and local or limited excision can be recom-
mended, but this should be patient tailored at multidisci-
plinary NET centers of excellence. Netazepide is also be-
ing tested in a trial enrolling patients with type 2 neo-
plasms [NCT01322542].
 In patients with type 3 g-NENs, while endoscopic 
management for small lesions has been proposed  [1, 28] , 
surgical treatment remains the recommended option and 
follows the strategy employed for gastric adenocarcino-
mas (partial or total gastrectomy with lymph node dissec-
tion). Systemic therapies are required for inoperable or 
stage 4 disease. 
 For d-NENs, endoscopic management has been prov-
en to be safe and effective for lesions  ≤ 10 mm in size, 
confined to the submucosal layer, without lymph node or 
distant metastasis ( fig. 2 ). In a series of 38 patients diag-
nosed over a 5-year period, no recurrence was observed 
at a mean follow-up of 17 months, and ESD achieved a 
higher rate of radical excision than EMR  [24] . Surgery 
should be performed for suspected T2 tumors or in those 
with positive margins after resection (local excision and 
antrectomy or total gastrectomy depending on tumor-
histological features and invasion). 
EUS: staging
ଯ
if tumors <1 cm – surveillance, or
endoscopic resection of all polyps
(ESD or EMR)
Laboratory
- FBC
- B12
- Parietal cell and intrinsic
 factor antibodies
- Check thyroid function 
Conservative management
- Lab + clinical control
 every 6–12 months
- OGD + biopsies and/or
 polyp resection every 
 12–24 months
Diagnosis
- Chronic atrophic body gastritis
- g-NENs (type 1)
Gastroscopy + biopsies
(1) Tumor(s)
(2) Gastric mucosa: fundus/body,
  antrum and duodenum
g-NENs
(usually discovered in the context
of anemia/dyspepsia
 Fig. 1. Algorithm for type 1 g-NEN management. EUS = Endo-
scopic ultrasonography; FBC = full blood count; OGD = oesopha-
geal gastroduodenal endoscopy. 
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 Follow-Up 
 Endoscopic follow-up is recommended for patients 
with g- and d-NENs following excision, but the correct 
timing has never been defined. It is recommended that 
patients undergo endoscopy at least every 2 years. For 
type 1 g-NENs, an approach based on tumor recurrence 
has been proposed, but it has never been validated in pro-
spective trials. Patients with CAG also require careful sur-
veillance for apparition of intestinal metaplasia and dys-
plasia using modern endoscopic equipment  [29, 30] .
 Please also refer to the ENETS consensus guideline up-
dates for other gastroenteropancreatic neuroendocrine 
tumors [ 31–36 , this issue].
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 Fig. 2. Algorithm for d-NENs. EUS = Endoscopic ultrasonography; N+ = positive lymph nodes; M+ = positive for 
metastasis; CHT = chemotherapy. 
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